Skip to main content
Wiley Open Access Collection logoLink to Wiley Open Access Collection
. 2022 Mar 10;28(20):e202104614. doi: 10.1002/chem.202104614

Late‐Stage Chemoenzymatic Installation of Hydroxy‐Bearing Allyl Moiety on the Indole Ring of Tryptophan‐Containing Peptides

Nagaraju Mupparapu 1, Lauren Brewster 1, Katrina F Ostrom 1, Sherif I Elshahawi 1,
PMCID: PMC9314954  PMID: 35178791

Abstract

The late‐stage functionalization of indole‐ and tryptophan‐containing compounds with reactive moieties facilitates downstream diversification and leads to changes in their biological properties. Here, the synthesis of two hydroxy‐bearing allyl pyrophosphates is described. A chemoenzymatic method is demonstrated which uses a promiscuous indole prenyltransferase enzyme to install a dual reactive hydroxy‐bearing allyl moiety directly on the indole ring of tryptophan‐containing peptides. This is the first report of late‐stage indole modifications with this reactive group.

Keywords: allylation, biocatalysis, C−H activation, functionalization, indole prenyltransferase


The late‐stage functionalization of indole‐ and tryptophan (Trp)‐containing compounds with reactive moieties facilitates downstream diversification and leads to changes in their biological properties. The synthesis of two hydroxy‐bearing allyl pyrophosphates is described and a chemoenzymatic method is demonstrated which uses a promiscuous indole prenyltransferase (IPT) enzyme to install a dual reactive hydroxy‐bearing allyl group directly on the indole ring of tryptophan‐containing peptides.

graphic file with name CHEM-28-0-g006.jpg


The selective cleavage of a carbon−hydrogen (C−H) bond of final or intermediate compounds to form a C−C or a C‐heteroatom (C−X) bond streamlines existing derivatization approaches. This late‐stage functionalization, particularly in the context of heterocycle‐containing complex compounds, leads to the formation of highly activated systems and provides access to bioactive analogs.[ 1 , 2 ] Yet, this C−H functionalization usually requires transition metals in addition to a high level of stereo‐, regio‐, and chemoselectivity. [3] An example of C−H activation includes allylic alkylation which has facilitated significant reactions such as the synthesis of indole‐derived isatins [4] and oxo‐functionalized eburnane alkaloids. [5] Another remarkable form of C−H activation is the introduction of a hydroxy group. Late‐stage hydroxylation changes the physical and chemical properties of compounds and enables downstream modifications without additional steps of protection/ deprotection.[ 2 , 6 ] Furthermore, hydroxylation of molecules allows for the formation of extended network of hydrogen bonds with biomolecules altering their biological activities. [6]

Hydroxy‐bearing allyl (HBA) moiety is one of the most recognized oxyfunctionalized entities as it carries two reactive groups, allyl and alcohol. The presence of HBA enabled the synthesis of complex molecules such as the antibiotic precursor 6‐deoxyerythronolide [7] and the polyene pheromone navenone B [8] from late‐stage intermediates. Moreover, the presence of HBA facilitated impressive downstream chemical reactions such as Sharpless epoxidation, [9] intramolecular cyclization, [10] and rearranged enone formation, [11] in addition to alkylation [12] and chlorination [13] reactions. The installation of HBA is challenging and has been achieved via hydroxylation of compounds containing allylic groups in multi‐step reactions. [14] Yet, no late‐stage direct installation of HBA has been reported due to its reactive nature.

Indole‐ and tryptophan (Trp)‐containing compounds are known for their biological activities. [15] Activation of this electron‐rich heteroaromatic system has attracted attention either at early [16] or late [17] stage. Approaches of indole prenylation, [18] alkylation, [16] or hydroxylation [19] have been reported (Figure 1a) and used for the synthesis of complex bioactive compounds.[ 4 , 5 ] Trp and indole‐containing compounds have also been modified using enzymes such as indole prenyltransferases (IPTs). [20] IPTs catalyze the transfer of a prenyl group, usually from native dimethylallyl, geranyl or farnesyl pyrophosphate donors, to Trp and other indole‐derived acceptors. Several IPTs have relaxed substrate specificities allowing them to catalyze C−C bond formation between nonnative acceptors and donors.[ 21 , 22 ] Our lab and others have reported the diversification of Trp‐containing simple[ 21 , 22 ] and complex[ 21 , 23 , 24 ] peptides with alkyl/aryl groups using IPTs. Yet, no reports included an HBA or even a hydroxy‐containing moiety (Figure 1b). We hypothesized that we can synthesize HBA pyrophosphate analogs that structurally resemble the IPTs native donor substrate dimethylallylpyrophosphate (DMAPP). We can then exploit a promiscuous IPT to facilitate the late‐stage installation of HBA on Trp‐containing peptides.

Figure 1.

Figure 1

Previous and current introduction of allyl and/or hydroxy groups on indole‐derived compounds. a) previously reported late‐stage allylic alkylation (i and ii)[ 16 , 17 , 18 ] and hydroxylation (iii) [19] catalyzed by transition metals, indole prenyltransferases (IPTs) [21] or other methods. b) Aim of current study. Hydroxy‐bearing allyl (HBA) group shown in red.

In this report, we strategically synthesize two HBA pyrophosphate isomers, (E)‐1‐hydroxy‐3‐methyl‐2‐buten‐4‐yl diphosphate (4a) and (E)‐1‐hydroxy‐2‐methyl‐2‐buten‐4‐yl diphosphate (4b) (Scheme 1). We install one of the HBA precursors, 4b enzymatically on the indole ring of mature peptides using an IPT enzyme. We determine the regiospecificities of the products using HR‐ESI‐MS and 1‐ and 2D NMR to be C‐5/C‐6/C‐3 and C‐5 selectively on the Trp of simple and complex peptides, respectively.

Scheme 1.

Scheme 1

Synthesis of 4a and 4b HBA pyrophosphates. Dimethylallyl fragment of native acceptor DMAPP is highlighted. Purified yields after column chromatography are stated.

First, we achieved the synthesis of 4a and 4b using key Wittig ylides and corresponding carbonyls (Scheme 1) different than what was previously reported for 4b.[ 25 , 26 , 27 ] Chloroacetone 1 and ethyl(triphenylphosphoranylidene)acetate were used to synthesize 2a while the glycolaldehyde dimer 5, ethyl 2‐(triphenylphosphoranylidene)‐propionate and N‐chlorosuccin‐ amide were used to synthesize 2b. Both chloroalkyl esters 2a/2b were reduced with diisobutylaluminum hydride (DIBAL−H) to provide 3a/3b followed by reaction with TBAPP and ion exchange chromatography to provide (E)‐4a/4b (Scheme 1). Strong NOE correlations confirmed the E‐configurations of C‐2′′/C‐3′′ in both compounds.

Next, we had the nucleic acid sequences encoding three promiscuous IPTs, PriB, [21] FgaPT2 [28] and CdpNPT [29] synthesized (Figures S1–S3). We evaluated the ability of any of the purified enzymes to couple 4a and/or 4b to simple cyclic Trp‐containing dipeptides. Cyclo‐(l‐Trp‐l‐Trp) 7, cyclo‐(l‐Trp‐l‐Tyr) 8 and cyclo‐(l‐Trp‐Gly) 9 were chosen as representatives (Figure 2a). Analytical scale reactions were carried out after optimization by incubating 0.4 mM of each of 79 and 1.6 mM of each of 4a or 4b with 33.6 μM of one of the above enzymes in 50 mM Tris buffer (pH 8.0) with (FgaPT2 and CdpNPT) and without (PriB) 10 mM CaCl2 at 37 °C for 16 h (Figure 3a). Negative controls lacking enzyme under the same conditions were also included. HPLC and HPLC‐MS of the quenched reactions revealed the formation of new products when each of 79 was incubated with 4b and CdpNPT but not 4a or any other tested enzyme. (Figures S5–S7, Table S1). This data is consistent with the higher promiscuity of CdpNPT compared to other IPTs.[ 22 , 23 , 24 ] Due to the higher total conversion yield of 4b with 7 (34 %) compared to 8 (12.4 %) and 9 (1.7 %), we sought to determine the Michaelis constant (K m) as well as the turnover number k cat of CdpNPT with 7/4b using GraphPad Prism 9.1.2. Subsequent determination of CdpNPT steady‐state kinetic parameters of 7/4b showed the total catalytic efficiency to be 0.51 M−1 s−1 (Figure S8), two‐fold lower than when coupling simple dipeptides with alkyl pyrophosphates. [23] The optimized reaction of 7/4b produced 11 [Figure 3; 11a (10.0 %), 11b (8.1 %), 11c (6.7 %) and 11d (9.4 %)].

Figure 2.

Figure 2

Tryptophan‐containing peptides used in this study. Structures of a) cyclic dipeptides 79; b) daptomycin 10.

Figure 3.

Figure 3

Chemoenzymatic method used and products obtained. a) CdpNPT‐catalyzed reaction between 4b and Trp‐containing dipeptides 79. Reaction conditions: 79 (0.4 mM), 4b (1.6 mM), 33.6 μM CdpNPT, in 50 mM TrisCl/ 10 mM CaCl2 at 37 °C for 16 h; b) structures of HBA‐modified products of cyclo‐(l‐Trp1l‐Trp2), 11a11d confirmed by HR‐MS and 1‐ and 2D NMR spectroscopy. 11d is probably an artifact that arose from HPLC conditions.

To identify the structures of the modified dipeptides, we scaled up the reaction between 7 and 4b using the optimized analytical conditions. Reactions in Tris 50 mM (pH 8.0) supplemented with 10 mM CaCl2 containing 2.3 mM 7, 1.8 mM 4b and 46 μM CdpNPT were incubated at 37 °C for 16 h. Preparative RP‐HPLC chromatography led to the purification of four modified dipeptides 11a11d with total isolated yields of 26 %. The (+)‐HR‐ ESI‐MS of 11a11c showed m/z [M+H]+ 457.2246, 457.2251 and 457.2196, respectively, indicating a molecular formula of C27H28N4O3 (calculated as 457.2234) and a Δm/z of 84 compared to the parent 7 suggesting an extra −C5H8O−. The 1‐ and 2D NMR spectroscopy of 11a and 11b reveals a C‐1′′ hydroxy‐prenylated group at C‐6 and C‐5, respectively (Figure 3b, Figures S9–S10, Table S2, see Experimental Section for detailed structural elucidation). In addition to the HBA‐dipeptides 11a and 11b, we also obtained 11c and 11d. Full NMR spectral data for 11c showed a C‐3′′ hydroxy‐prenylated group at the indole C‐3 with a subsequent formation of C−N bond between C‐2 and N‐10 generating a hexahydropyrrolo‐[2,3‐b]indole structure (Figure 3b, Figures S11–S12, Table S3, see Experimental Section for detailed structural elucidation) typical of other prenylated analogs. [22] The HRMS of 11d indicated a molecular formula of C28H28N4O4 and NMR data were consistent with that of 11c with an additional formyl group at N‐1 suggesting 11d to be an artifact of HPLC conditions of 11c. This highlights the selectivity of CdpNPT to modify the indole ring of Trp‐containing dipeptides yet with moderate regiospecificities. Thus, we synthesized four HBA‐modified dipeptides selectively at the Trp moiety (Figure 3b).

We sought to determine if our methodology can be used to modify a larger, more reactive and more diverse Trp‐containing peptide such as the cyclic tridecapeptide, daptomycin [30] 10 with HBA (Figure 2b). Thus, analytical assays were carried out after optimization using 0.8 mM of 10, 1.6 mM of each of 4a and 4b and 25.2 μM of one of the three IPTs and incubated in 50 mM Tris (pH 8.0) with and without CaCl2 at 37 °C for 16 h. Similar to reactions with dipeptides 79, only reactions with 4b not 4a and with only CdpNPT showed a new product. In contrast to 79, only one single product 12 was formed (Figure 4a). To identify the regiospecificity of 12, large‐scale reaction containing 0.8 mM 10, and 2.0 mM of 4b and 32 μM CdpNPT incubated in 50 mM Tris/10 mM CaCl2 (pH 8.0) at 37 °C for 16 h was carried out. Preparative RP‐HPLC purification led to a single modified daptomycin product with isolated yield of 15 %. The (+)‐HR‐ESI‐MS indicated a molecular formula of C77H109 N17O27, an additional −C5H8O− compared to 10. 1‐ and 2D NMR data revealed 12 to be 5‐C‐((E)‐4‐hydroxy‐3‐methylbut‐2‐en‐1‐yl)‐l‐Trp1 daptomycin (Figures 4b–4c, Figure S13, Table S4; see Experimental Section for detailed structural elucidation).

Figure 4.

Figure 4

Derivatization of daptomycin 10 with HBA group. a) HPLC analysis of in vitro assays containing 10 (0.8 mM) with 4a or 4b (1.6 mM) in Tris 50 mm/CaCl2 10 mm (pH 8.0) incubated with CdpNPT (32 μM) for 16 h at 37 οC. b) 1H‐1H COSY, 1H−13C HMBC and 1H‐1H NOESY correlations of the tryptophan of 12 (full NMR correlations are demonstrated in Figure S13). c) Structure of HBA‐modified daptomycin 12. Long‐range 1H−1H COSY correlations are shown between H‐2′′/H‐4′′, H‐5′′.

In this study, we synthesize two HBA‐pyrophosphates (Scheme 1) and use one substrate for the direct installation of HBA on the indole ring of Trp‐containing peptides. The fact that 4b, not 4a was accepted by CdpNPT might be due to the closer structural resemblance of 4b to the enzyme native donor DMAPP compared to 4a. Moreover, upon the release of the diphosphate from 4a or 4b, an allyl carbocation is formed. The 4b allyl carbocation formed is stabilized by hyperconjugation with the 3′′‐methyl C−H and the allyl σ‐bonds [31] allowing it to have more resonance structures than the 4a carbocation. This increases the stability of 4b and facilitates the reaction between the nucleophilic indole and the electrophilic donor species. [20] To our knowledge, this is the first report for the synthesis of 4a while 4b has been previously reported using different approaches and starting materials.[ 25 , 26 , 27 ] In addition to their role in late‐stage biocatalytic diversification of Trp residues shown here, 4a/4b can act as substrates for other diphosphate‐utilizing enzymes such as terpene cyclases and other prenyltransferases. Using different HBA pyrophosphate substrates with variable enzymes has the potential to diversify natural products and other compounds. Moreover, substrate 4b was shown to be a strong phosphoantigen activator of the Vγ9/Vδ2T of the γδ T‐cells involved in immune responses to many diseases and fighting tumor cells. [32] Due to structural resemblance of 4a with 4b, we propose similar activity which urges the need for further immunological studies.

We report a selective late‐stage functionalization method for the direct installation of an HBA group onto the Trp indole ring via a chemoenzymatic approach (Figure 3a). This method directly and selectively modifies the Trp indole ring and allows the diversification of Trp‐containing peptides with an allyl alcohol group without the need for laborious de novo chemical synthesis. Peptide functionalization have gained great interest as it used as a tool for drug discovery and understanding diseases. [33] Indeed, several groups have functionalized Trp‐containing peptides using chemical and photochemical methods.[ 34 , 35 ] However, direct installation of a dual reactive functionality, allyl and alcohol, that enables streamline downstream modifications to target either one or both groups simultaneously is unprecedented. No enzyme has been reported to install an HBA or free hydroxy group on aromatic moieties of complex compounds or peptides. Our one‐step method is carried out in aqueous buffer under mild conditions of ambient temperature and pH using a wild‐type enzyme and requires no directing groups or tedious enzyme engineering efforts. The Trp‐containing peptides tested in this study are chemically diverse and in the case of 10 contains several acidic, basic and polar groups. Yet, only Trp‐HBA derivatives were obtained highlighting the selectivity of our method towards the Trp residue in peptides. No diprenylated products were detected with any tested substrates by HPLC or HRMS even on the two Trp residues‐containing, 7. Despite the fact that multiple products were reported with CdpNPT when coupling dipeptides with other alkyl pyrophosphates, C‐5 modification was never shown. [22] The increase in conversion yield of 7 compared to either 8 or 9 could be attributed to its higher hydrophobic character and proper size that properly fits into the enzyme active site. [36] Although 11c and 11d do not contain a typical allyl alcohol group, they contain vinyl and alcohol moieties which are also reactive and prone to further derivatization. In addition to the dual reactive group installed, 11c and 11d have undergone another remarkable NC bond formation converting the cyclodipeptide to hexahydropyrrolo[2,3‐b]indole core which is characteristic of several promising biologically active alkaloids. [37] In the case of dipeptides, regiospecificity was moderate giving rise to multiple products (Figure 3b) while with the larger peptide 10, one single product was obtained (Figure 4a, Figure 4c). This is probably attributed to the steric restraint of 10 in the IPT active site preventing different orientations compared to the simpler 79 (Figure 4a, 4c). Noteworthy, the Trp C‐5 position of 10 was reported to be less accessible to enzymatic functionalization when coupled with any alkyl substrates. [24] However, 4b entirely favored accessing the C‐5 position with 10. We provide a proof of concept that HBA can be installed selectively on Trp and suggest that yield and regiospecificity can be improved via screening of other wildtype IPTs and/or engineering efforts as well as using enzyme immobilization techniques. This work highlights the significance of enzymes in catalyzing difficult chemical reactions, in addition to their established role in the biosynthesis of complex natural products[ 38 , 39 ] and resistance against producing hosts. [40]

In short, we synthesized two HBA pyrophosphate isomers with good yield. We developed a method to selectively use these isomers to functionalize the indole ring of the Trp C−H bond of representative peptides with a dual reactive HBA moiety. The method directly modifies the indole ring at multiple sites in the case of small peptides but one specific C‐5 modified product was synthesized with a complex tridecapeptide, 10. The late‐stage direct installation of two reactive nucleophilic groups, hydroxyl and allyl, is unprecedented and opens the door for future downstream derivatizations, bioorthogonal chemical reactions, bioconjugation and modulation of the biological activities of Trp‐containing peptides and indole‐derived compounds.

Conflict of interest

The authors declare no conflict of interest.

Supporting information

As a service to our authors and readers, this journal provides supporting information supplied by the authors. Such materials are peer reviewed and may be re‐organized for online delivery, but are not copy‐edited or typeset. Technical support issues arising from supporting information (other than missing files) should be addressed to the authors.

Supporting Information

Acknowledgements

We thank the Chapman University School of Pharmacy (CUSP) and the core lab facility for supporting this work as well as Dr. Innokentiy Maslennikov and the Nuclear Magnetic Resonance facility for NMR measurements. We are grateful to graduate and undergraduate students, Ahmed Aoun, Yu‐Hsin (Cindy) Lin, Christopher Nguyen and Zhengfeiyue (Chelsea) Pan for assistance in enzyme overproduction and purification as well as screening assays and to Basir Syed for technical assistance.

N. Mupparapu, L. Brewster, K. F. Ostrom, S. I. Elshahawi, Chem. Eur. J. 2022, 28, e202104614.

Data Availability Statement

The data that support the findings of this study are available in the supplementary material of this article.

References

  • 1. Loskot S. A., Romney D. K., Arnold F. H., Stoltz B. M., J. Am. Chem. Soc. 2017, 139, 10196–10199. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2. Narayan A. R. H., Jiménez-Osés G., Liu P., Negretti S., Zhao W., Gilbert M. M., Ramabhadran R. O., Yang Y.-F., Furan L. R., Li Z., Podust L. M., Montgomery J., Houk K. N., Sherman D. H., Nat. Chem. 2015, 7, 653–660. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3. Wencel-Delord J., Glorius F., Nat. Chem. 2013, 5, 369–375. [DOI] [PubMed] [Google Scholar]
  • 4. Trost B. M., Kalnmals C. A., Ramakrishnan D., Ryan M. C., Smaha R. W., Parkin S., Org. Lett. 2020, 22, 2584–2589. [DOI] [PubMed] [Google Scholar]
  • 5. Trost B. M., Bai Y., Bai W.-J., Schultz J. E., J. Am. Chem. Soc. 2019, 141, 4811–4814. [DOI] [PubMed] [Google Scholar]
  • 6. White M. C., Zhao J., J. Am. Chem. Soc. 2018, 140, 13988–14009. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7. Stang E. M., Christina White M., Nat. Chem. 2009, 1, 547–551. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8. Li P.-F., Wang H.-L., Qu J., J. Org. Chem. 2014, 79, 3955–3962. [DOI] [PubMed] [Google Scholar]
  • 9. Lichtor P. A., Miller S. J., Nat. Chem. 2012, 4, 990–995. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10. Bairy G., Das S., Begam H. M., Jana R., Org. Lett. 2018, 20, 7107–7112. [DOI] [PubMed] [Google Scholar]
  • 11. Li J., Tan C., Gong J., Yang Z., Org. Lett. 2014, 16, 5370–5373. [DOI] [PubMed] [Google Scholar]
  • 12. Yang B., Wang Z.-X., J. Org. Chem. 2020, 85, 4772–4784. [DOI] [PubMed] [Google Scholar]
  • 13. Vázquez-Romero A., Gómez A. B., Martín-Matute B., ACS Catal. 2015, 5, 708–714. [Google Scholar]
  • 14. Joannou M. V., Moyer B. S., Meek S. J., J. Am. Chem. Soc. 2015, 137, 6176–6179. [DOI] [PubMed] [Google Scholar]
  • 15. Kaushik N. K., Kaushik N., Attri P., Kumar N., Kim C. H., Verma A. K., Choi E. H., Molecules 2013, 18, 6620–6662. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16. Dachwitz S., Scharkowski B., Sewald N., Chem. Eur. J. 2021, 27, 18043–18046. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17. Gruß H., Sewald N., Chem. Eur. J. 2020, 26, 5328–5340. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18. Ruchti J., Carreira E. M., J. Am. Chem. Soc. 2014, 136, 16756–16759. [DOI] [PubMed] [Google Scholar]
  • 19. Kugel S., Baunach M., Baer P., Ishida-Ito M., Sundaram S., Xu Z., Groll M., Hertweck C., Nat. Commun. 2017, 8, 15804. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20. Walsh C. T., ACS Chem. Biol. 2014, 9, 2718–2728. [DOI] [PubMed] [Google Scholar]
  • 21. Elshahawi S. I., Cao H., Shaaban K. A., Ponomareva L. V., Subramanian T., Farman M. L., Spielmann H. P., Phillips G. N., Thorson J. S., Singh S., Nat. Chem. Biol. 2017, 13, 366–368. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22. Liebhold M., Xie X., Li S.-M., Org. Lett. 2013, 15, 3062–3065. [DOI] [PubMed] [Google Scholar]
  • 23. Mupparapu N., Lin Y.-H. C., Kim T. H., Elshahawi S. I., Chem. Eur. J. 2021, 27, 4176–4182. [DOI] [PubMed] [Google Scholar]
  • 24. Scull E. M., Bandari C., Johnson B. P., Gardner E. D., Tonelli M., You J., Cichewicz R. H., Singh S., Appl. Microbiol. Biotechnol. 2020, 104, 7853–7865. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25. Hecht S., Amslinger S., Jauch J., Kis K., Trentinaglia V., Adam P., Eisenreich W., Bacher A., Rohdich F., Tetrahedron Lett. 2002, 43, 8929–8933. [Google Scholar]
  • 26. Fox D. T., Poulter C. D., J. Org. Chem. 2002, 67, 5009–5010. [DOI] [PubMed] [Google Scholar]
  • 27. Chaignon P., Petit B. E., Vincent B., Allouche L., Seemann M., Chem. Eur. J. 2020, 26, 1032–1036. [DOI] [PubMed] [Google Scholar]
  • 28. Unsöld I. A., Li S.-M., Microbiology 2005, 151, 1499–1505. [DOI] [PubMed] [Google Scholar]
  • 29. Yin W.-B., Ruan H.-L., Westrich L., Grundmann A., Li S.-M., ChemBioChem 2007, 8, 1154–1161. [DOI] [PubMed] [Google Scholar]
  • 30. Nguyen K. T., Ritz D., Gu J.-Q., Alexander D., Chu M., Miao V., Brian P., Baltz R. H., Proc. Natl. Acad. Sci. U. S. A. 2006, 103, 17462–17467. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31. Mayr H., Foerner W., von R. Schleyer P., J. Am. Chem. Soc. 1979, 101, 6032–6040. [Google Scholar]
  • 32. Morita C. T., Jin C., Sarikonda G., Wang H., Immunol. Rev. 2007, 215, 59–76. [DOI] [PubMed] [Google Scholar]
  • 33. Struck A.-W., Bennett M. R., Shepherd S. A., Law B. J. C., Zhuo Y., Wong L. S., Micklefield J., J. Am. Chem. Soc. 2016, 138, 3038–3045. [DOI] [PubMed] [Google Scholar]
  • 34. Hansen M. B., Hubálek F., Skrydstrup T., Hoeg-Jensen T., Chem. Eur. J. 2016, 22, 1572–1576. [DOI] [PubMed] [Google Scholar]
  • 35. Yu Y., Zhang L.-K., Buevich A. V., Li G., Tang H., Vachal P., Colletti S. L., Shi Z.-C., J. Am. Chem. Soc. 2018, 140, 6797–6800. [DOI] [PubMed] [Google Scholar]
  • 36. Schuller J. M., Zocher G., Liebhold M., Xie X., Stahl M., Li S.-M., Stehle T., J. Mol. Biol. 2012, 442, 87–89. [DOI] [PubMed] [Google Scholar]
  • 37. Ruiz-Sanchis P., Savina S. A., Albericio F., Álvarez M., Chem. Eur. J. 2011, 17, 1388–1408. [DOI] [PubMed] [Google Scholar]
  • 38. Elshahawi S. I., Trindade-Silva A. E., Hanora A., Han A. W., Flores M. S., Vizzoni V., Schrago C. G., Soares C. A., Concepcion G. P., Distel D. L., Schmidt E. W., Haygood M. G., Proc. Natl. Acad. Sci. U. S. A. 2013, 110, E295–304. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 39. Clinger J. A., Zhang Y., Liu Y., Miller M. D., Hall R. E., Van Lanen S. G., Phillips G. N., Thorson J. S., Elshahawi S. I., ACS Chem. Biol. 2021, 16, 2816–2824. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 40. Elshahawi S. I., Ramelot T. A., Seetharaman J., Chen J., Singh S., Yang Y., Pederson K., Kharel M. K., Xiao R., Lew S., Yennamalli R. M., Miller M. D., Wang F., Tong L., Montelione G. T., Kennedy M. A., Bingman C. A., Zhu H., Phillips G. N., Thorson J. S., ACS Chem. Biol. 2014, 9, 2347–2358. [DOI] [PMC free article] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

As a service to our authors and readers, this journal provides supporting information supplied by the authors. Such materials are peer reviewed and may be re‐organized for online delivery, but are not copy‐edited or typeset. Technical support issues arising from supporting information (other than missing files) should be addressed to the authors.

Supporting Information

Data Availability Statement

The data that support the findings of this study are available in the supplementary material of this article.


Articles from Chemistry (Weinheim an Der Bergstrasse, Germany) are provided here courtesy of Wiley

RESOURCES